The development of human cancer is a highly complex process and can be considered the result of several combined events, such as genetic alterations, disturbance of signal transduction, or failure of immunological surveillance. Cancer-related databases usually focus on specific fields of research, e.g., cancer genetics or cancer immunology, whereas the complexity of cancer genesis requires an integrated analysis of heterogeneous data from several sources. Here we present the cancer-associated protein database (CAP), a novel analysis system for cancer-related data. CAP integrates data from multiple external databases, augments these data with functional annotations, and offers tools for statistical analysis of these data. We have employed CAP to analyze genes that have been found to cause an autoimmune response in cancer. In particular, we explored the connection between the autoimmune response, mutations, and overexpression of these genes. Our preliminary results suggest that mutations are not significant contributors to raising an antibody response against tumor antigens, whereas overexpression seems to play a more important role. We hereby demonstrate how different types of data can be integrated and analyzed successfully, providing interesting results. As the amount of available data is growing rapidly, a combined analysis will play an important role in exploring the genetic and immunological basis of cancer. CAP is freely available at the following web site: http://www.bioinf.uni-sb.de/CAP/.
available from databases such as SWISS-PROT (2), NCBI, and Locus Link (3) .
Combining this vast amount of data is a challenge, and it is the key to revealing the complex mechanisms of cancer genesis and development. One major thing to consider when performing a covering analysis is the differences in data formats (syntactic differences) and differences in the meaning of the data (semantic differences) (4) in these databases. Those differences have to be resolved to create a unified view of the data.
Here we present the cancer-associated protein database (CAP), a novel integrated database and analysis system, designed to integrate heterogeneous data from different sources. CAP annotates this data with predictions from bioinformatics and facilitates statistical analyses. CAP has been implemented as a relational database system with a web-based interface for portable and userfriendly access. It integrates data from the SEREX database, CGW, NCBI, and SWISS-PROT. These data can then be further annotated in CAP. Currently, annotations added include prediction of protein function (ProtFun; refs 5-6), presence of MHC epitopes (SVMHC; ref 7) , and subcellular location (PSORT; ref 8; and SubLoc; ref 9) .
CAP provides customizable forms for importing user-specific experimental data. It also allows the grouping of data into problem-specific datasets. The data can be viewed, edited, and annotated through a user-friendly web-based interface. Furthermore, CAP provides tools for the statistical analysis of user-defined datasets. The results of these analyses can be either exported as tables for further use or rendered as graphs.
As a first application, we have examined a set of cancer-related genes and gene products causing an autoimmune response. We have studied the connection between mutations and immunogenicity. We analyzed data obtained from SEREX experiments for alterations and mutations by correlating it with data from Cancer GeneticsWeb. Out of 723 from SEREX and the 606 genes contained in CGW, we found only 17 genes occurring in both datasets. Seven of these genes were related to the same cancer type. Of these seven, only two (TP53 and GSTT1) are known to carry specific mutations or polymorphisms, whereas the remaining five are overexpressed in the respective tumors.
A second analysis correlates all cancer-related genes in CAP, found by SEREX experiments, with expression data from the NCI60 microarray project (10) . We considered all genes that show a twofold or higher overexpression. In total, 319 genes occur in both CAP and the NCI60 dataset; 277 of these genes were overexpressed in at least one of the NCI60 cell lines, while 69 were overexpressed in at least 10% of the cell lines. For 13 overexpressed genes, in at least 3 tumor type specific cell lines, we found agreement between the cancer type of the SEREX experiment and the cancer type associated with the respective NCI60 cell line.
In this report, we describe the overall design of CAP and give a brief overview of its abilities. Furthermore, we describe and discuss the results of our analysis in more detail. CAP is accessible at the following web site: http://www.bioinf.uni-sb.de/CAP/.
MATERIALS AND METHODS

Content of CAP
The data in CAP originate from several sources; the main contributing ones and their URLs are listed in Table 1 . An overview of how information from these sources has been combined is given in Fig. 1 .
Information collected about nucleic acid (NA) and protein (PROT) sequences is both general as well as cancer specific. In addition, CAP automatically augments the data by annotating it with sequence-based prediction of their genes and their products, e.g., subcellular location and presence of MHC epitopes.
Data sources
Two major sources of information are the NCBI's Reference Sequence Project (RefSeq) and the SWISS-PROT database. RefSeq provides a well-annotated nonredundant set of cDNA, protein, and genomic sequences. RefSeq provides standards for gene characterization, mutations, and polymorphisms. SWISS-PROT is a low-redundancy curated database focusing on proteins. Information therein includes protein function annotations, domain structure, posttranslational modifications, and protein subcellular location.
SEREX (serological analysis of recombinant cDNA expression libraries) is a screening method for detecting antibodies raised against tumor-expressed antigens (1) . An experimental NA sequence, tumor type, and antibody response are typical features of a SEREX experiment. SEREX-related information in CAP originates from our own experiments (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , unpublished data, and the SEREX database. The SEREX database itself is currently in a read-only mode; however, it is being contained in the Cancer Immunome Database (CIDB).
CGW provides information about cancer-related genes. The majority of listed genetic abnormalities have as of yet only been found in nonhereditary tumors.
For the analysis of genes in relation to mutations and immunogenicity, the status of CAP and CGW from December 1, 2003 was used. Information extracted from external databases is updated on a regular basis.
Predictions
A number of different prediction methods have been integrated into CAP. These cover prediction of protein subcellular location, function, and MHC class I epitopes.
Only a subset of all existing proteins has been assigned to an experimentally detected subcellular location in SWISS-PROT. Knowledge of subcellular location of a protein is crucial, both for its experimental analysis, including the identification of its interaction partners, and for the understanding of its overall function.
Prediction methods aiming to assign location on a proteome-scale include two main approaches. One is based on signal peptide identification, postulating the final destination of a protein.
Another approach uses the total amino acid composition for discrimination between subcellular locations. The two methods used in CAP are PSORT (8) and SubLoc (9) . The former is based on a decision tree model and the latter on a support vector machine approach.
Predicting protein function is a nontrivial task, due to the wide spectrum of possible functions, the existence of proteins carrying out multiple functions, and various ways of defining function. For predicting function, we use the ProtFun 2.1 server (5-6), which predicts functional category, enzyme class, and gene ontology category.
Putative T cell epitopes of a protein are good candidates in the development of cancer therapies and treatments. SVMHC (7) is a method for predicting potential T cell epitopes that is integrated into CAP.
Data modeling
The CAP data model is designed to accommodate and integrate different types of biological data, which is very heterogeneous by nature. A generalization of the model is shown in Fig. 2 . The Unified Modeling Language (UML) was used for modeling (21) . UML gives a well-defined data model that can easily be extended to include new data types.
The CAP model is centered on PROT and NA sequences, which can be of either reference type or experimental. A reference sequence typically originates from the RefSeq or SWISS-PROT databases, whereas an experimental sequence may come from a SEREX experiment. Fig. 2 are function, location, and alias. Most annotations in CAP contain some specific information, e.g., the function or location of a protein, and the source of information. A protein might for example have an annotated biological function, and the source of that annotation might be the SWISS-PROT database or a certain prediction method. Keeping track of the sources for annotations is one of the key concepts in CAP. Experimentally verified annotations are usually considered to be of higher confidence than predicted ones.
Sequences can be annotated with different annotations. The examples of annotations in
Sequences can be connected to other sequences, as well as to annotations. An NA sequence found in an experiment is typically mapped to an NA reference sequence by means of a BLAST search. The NA reference sequence is itself connected to a PROT reference sequence. The connections between sequences of different type allow for complex queries. One example is to extract subcellular location of proteins related to a set of experimentally found NA sequences, see Fig. 3 . Another feature of CAP is linking to external resources; an example of this is also shown in Fig. 3 .
Data inspection tools
The data in CAP are organized in a format appropriate for fast and flexible database searching. CAP provides several options for analyzing individual sequences in detail or sets of sequences concurrently. Single sequences can be grouped into datasets. There are also tools for editing datasets and to extract new datasets from existing ones.
Datasets can be analyzed in several ways, including chromosomal distribution of genes, function, and subcellular location of proteins. The following section exemplifies how CAP can be used in a complex analysis.
A set of NA sequences from SEREX experiments on lung cancer were submitted to CAP and grouped into a dataset called LUNG_EXP. Then, using the built-in CAP-tools for constructing datasets, their corresponding RefSeq NA and PROT sequences were retrieved, resulting in the two new datasets LUNG_NA and LUNG_PROT. A summary view of parts of the LUNG_PROT dataset can be seen in Fig. 4 . This view shows information about the dataset in table format. What will be displayed in the table is user defined and in this case the choice was sequence information, function, and subcellular location. This type of overview gives a first glance of the sequences at hand. A more statistical view of the subcellular locations in the LUNG_PROT dataset can be seen in Fig. 5 . The graph Distribution is the plain count of sequences from the dataset belonging to a certain subcellular location. Expected distribution is an estimation of the whole-proteome distribution of locations as described previously (22). Distribution -Expected distribution shows the difference between the two previous graphs. As can be seen in the plain distribution, a lot of the sequences are predicted to be located in the nucleus. The normalized graph, on the other hand, shows that this is not too surprising, since a rather large portion of all proteins are expected to be found in the nucleus. Other types of statistics that can be done on datasets are protein function and chromosomal distribution. Protein function is based on predictions by the ProtFun server (5-6). Chromosomal distribution is based on information from RefSeq and shows the number of genes from a dataset that is found on a certain chromosome.
RESULTS AND DISCUSSION
The usefulness of CAP can be exemplified by a large-scale analysis of cancer-related data. Genetic changes, gene expression levels, and failure of the immune system are important factors for tumor initiation and progression. We analyzed genes in CAP found by SEREX experiments for their overlap with CGW. Out of 723 genes extracted from CAP, we found 17 genes and 2 splice variants in CGW. This first step was done without any concern about the cancer types in which the genes were identified. Our next step was to look for genes that are found in the same cancer type in both SEREX experiments and CGW.
A total of seven genes were identified, including two genes carrying specific mutations or polymorphisms, TP53 and GSTT1 (glutathione S-transferase theta 1). TP53 has previously been found to cause immune responses in primary colon carcinoma and in breast carcinoma, both known to carry TP53 mutations (23-24). Mutations in TP53 have also been found in a large number of other tumor types in patients that do not have antibodies against TP53. As for GSTT1, antibody responses occur in patients with breast cancer. This tumor is associated with specific GSTT1 polymorphisms (25). However, these types of polymorphisms also occur in other tumors including head and neck cancer without an antibody response (26). Other examples of genes include NME2/NME1 (protein NM23B/A expressed in nonmetastatic cells 2/1), HSPCA (heat shock 90kD protein 1), Ki-67 (MKI67), and MIF (macrophage migration inhibitory factor). NME1 and NME2 have been reported as immunogenic and overexpressed in malignant colon carcinoma (27), HSPCA in renal cell carcinoma (28) , Ki-67 in melanoma (29) (30) , and MIF in melanoma (31) .
For analyzing expression levels, we used the gene expression profile data of the NCI60 microarray project (http://genome-www.stanford.edu/nci60/). In this project, cDNA microarrays are used to explore the variation of gene expression in 8,000 genes from 60 cancer cell lines. These 60 cell lines are also used by the National Cancer Institute for screening potential cancer drugs. The expression data provided by NCI include fluorescence ratios, normalized against a pool of 12 cancer cell lines.
Genes that show at least a twofold increase in expression levels are considered to be overexpressed. We also add the criteria that a certain gene must have measured expression levels in at least 4 of the 60 cell lines. This gives us expression levels for 319 CAP genes.
Independent of cancer type, we found 277 (87%) of the genes to be overexpressed in at least one cell line. Out of these 277 genes, 69 were found to have an overexpression in at least 10% of all evaluated cell lines. A more cancer-specific analysis was also done. The 60 cancer clones in the NCI60 data can be grouped into a number of cancer types, e.g., melanoma, breast cancer, or colon cancer. Expression levels for genes found in the same cancer type in both SEREX experiments and the NCI60 data were extracted. The criterion for selection was that at least 3 tumor specific cell lines show overexpression, giving a total of 13 genes. The genes and SEREX related information is presented in Table 2 .
It has been hypothesized that immunogenic antigens might stem from genes that are altered by tumor-specific mutations or have a changed expression profile in a certain tumor (reviewed in ref 32). Here we have used CAP to merge information from the fields of genetics and immunology. From available data, we see no evidence that genetic alterations, such as mutations or polymorphisms, cause immune responses in cancer. In terms of variations in expression, we see indications that overexpression contributes to the antibody responses against tumor antigens. The majority of the 319 genes are actually found to be overexpressed in the NCI60 dataset. This result might be somewhat biased from the selection of genes tested for expression levels. The NCI60 dataset was designed to explore the variation in gene expression among different cancer types.
It might be misleading to turn these findings into general rules concerning immune responses in cancer. We rather show that CAP makes this kind of analysis possible by integrating different sources of data.
A recent report pointed out the importance of future databases offering more than simple data retrieval and storage (33) . Furthermore, genetic aberrations in certain chromosomal regions and changes in gene-expression of such regions have been identified for certain cancer types (34) . Over-expressed genes have also been suggested as attractive therapeutic targets (35) . Protein function and subcellular location are important in the identification of protein interaction networks and signaling pathways targeted in cancer. CAP provides tools for statistical analysis of chromosomal distribution, protein function, and subcellular location, for sets of sequences. We believe that integration and analysis of heterogeneous data will help in the understanding of both the genetic and the immunological basis of cancer. An experimental NA sequence is typically related to a reference NA sequence. The NA sequence itself is connected to a PROT reference sequence. In this example, the PROT sequence has 3 annotations: 1 location and 2 aliases. Protein location for a sequence related to a NA sequence can easily be extracted, since all that information is connected. By using databases identifiers as aliases, it is possible to create hyperlinks to external databases. Linking to external data sources allows for fast extended information retrieval. 
